ArticleJournal of the American Society of Nephrology : JASN2016
Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals.
Article in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 113 citations in OpenAlex.
- Article
- Kidney diseases and the thyroid: interactions and consequences.Nature reviews. Endocrinology · 2026Review
- Critical considerations in the administration of antineoplastic therapy for patients with malignant solid tumors undergoing hemodialysis.Frontiers in oncology · 2026Review
- Immediate and Gradual Withdrawal of Immunosuppression After Kidney Graft Loss Lead to Similar Outcomes.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Increased cancer risk in kidney transplant patients in Scotland: a national registry linkage study.British journal of cancer · 2025Article
- Novel association between graft rejection and post-transplant malignancy in solid organ transplantation.World journal of transplantation · 2025Article
- Surgical Management of Renal Cell Carcinoma in Transplanted Kidneys-A Narrative Review.Cancers · 2025Review
- Renal cell carcinoma and upper tract urothelial carcinoma in kidney transplant recipients.Journal of medicine and life · 2025Article
- Renal Cell Carcinoma in Native Kidney After Kidney Transplantation: A Multicenter Case Control Study With a Focus on Screening Strategy.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Clinical features and mutational frequency of renal cell carcinoma from patients undergoing kidney transplant evaluation.Frontiers in oncology · 2025Article
- Urgent considerations on renal immune-related adverse events in oncology practice.Frontiers in immunology · 2025Review
- Article
- Cross-section of thyroidology and nephrology: Literature review and key points for clinicians.Journal of clinical & translational endocrinology · 2024Review
- Report on post-transplantation cancer in southeast Asia from the Thai kidney transplantation cohort.Scientific reports · 2024Article
- Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Article
- Current Trends and Future Directions of Malignancy After kidney Transplantation: A 1970-2022 Bibliometric Analysis.Annals of transplantation · 2024Article
- A Global Survey of Self-Reported Cancer Screening Practices by Health Professionals for Kidney Transplant Candidates and Recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Incidence ofTransplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Management of stage 1 renal cell cancer in patients immunosuppressed for organ transplantation or autoimmune disease.Frontiers in urology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Among patients with ESRD, cancer risk is affected by kidney dysfunction and by immunosuppression after transplant. Assessing patterns across periods of dialysis and kidney transplantation may inform cancer etiology. We evaluated 202,195 kidney transplant candidates and recipients from a linkage between the Scientific Registry of Transplant Recipients and cancer registries, and compared incidence in kidney function intervals (time with a transplant) with incidence in nonfunction intervals (waitlist or time after transplant failure), adjusting for demographic factors. Incidence of infection-related and immune-related cancer was higher during kidney function intervals than during nonfunction intervals. Incidence was most elevated for Kaposi sarcoma (hazard ratio [HR], 9.1; 95% confidence interval (95% CI), 4.7 to 18), non-Hodgkin's lymphoma (HR, 3.2; 95% CI, 2.8 to 3.7), Hodgkin's lymphoma (HR, 3.0; 95% CI, 1.7 to 5.3), lip cancer (HR, 3.4; 95% CI, 2.0 to 6.0), and nonepithelial skin cancers (HR, 3.8; 95% CI, 2.5 to 5.8). Conversely, ESRD-related cancer incidence was lower during kidney function intervals (kidney cancer: HR, 0.8; 95% CI, 0.7 to 0.8 and thyroid cancer: HR, 0.7; 95% CI, 0.6 to 0.8). With each successive interval, incidence changed in alternating directions for non-Hodgkin's lymphoma, melanoma, and lung, pancreatic, and nonepithelial skin cancers (higher during function intervals), and kidney and thyroid cancers (higher during nonfunction intervals). For many cancers, incidence remained higher than in the general population across all intervals. These data indicate strong short-term effects of kidney dysfunction and immunosuppression on cancer incidence in patients with ESRD, suggesting a need for persistent cancer screening and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.